LINC01648: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01648

NCBI ID: G101929406

LINC01648

Other Name(s): long intergenic non-protein coding RNA 1648 | Long intergenic non-protein coding RNA 1648

LINC01648: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01648 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential to regulate gene expression and play a role in the development and progression of various diseases, including cancer. Its unique feature is its long intergenic nature, which means it spans multiple gene exons and can interact with other long non-coding RNAs and proteins in the same gene or different genes. This property makes LINC01648 an attractive candidate for drug targeting or as a biomarker. In this article, we will explore the potential of LINC01648 as a drug target and its potential as a biomarker for various diseases.

Potential Drug Target

LINC01648 has been shown to play a role in the regulation of cell cycle progression and has been associated with the development of various cancers, including lung cancer, breast cancer, and colon cancer. Its long non-coding nature and its interaction with other non-coding RNAs and proteins make it a potential drug target. Researchers have identified several potential drug targets for LINC01648, including the androgen receptor, the estrogen receptor, and the NF-kappa-B signaling pathway. These drug targets are involved in various cellular processes that are relevant to cancer development and progression, including cell growth, apoptosis, angiogenesis, and inflammation. Therefore, targeting LINC01648 with small molecules or other therapeutic agents that can modulate its expression levels could be a promising strategy for cancer treatment.

Potential Biomarker

LINC01648 has also been identified as a potential biomarker for various diseases, including cancer. Its long non-coding nature and its interaction with other non-coding RNAs and proteins make it a potential candidate for disease biomarkers. Researchers have identified several biomarkers that can be regulated by LINC01648, including the expression of genes involved in cell adhesion, migration, and invasion, as well as genes involved in inflammation and immune response. These biomarkers can be used to diagnose, monitor, and treat various diseases, including cancer. Therefore, LINC01648 is a promising candidate as a biomarker for disease diagnosis and treatment.

Function and Interaction

LINC01648 is a long non-coding RNA that has been shown to play a role in the regulation of gene expression and cell biology. Its unique feature is its long intergenic nature, which means it spans multiple gene exons and can interact with other long non-coding RNAs and proteins in the same gene or different genes. LINC01648 has been shown to regulate the expression of various genes involved in cell cycle progression, apoptosis, angiogenesis, and inflammation.

One of the most significant functions of LINC01648 is its role in regulating the cell cycle. LINC01648 has been shown to play a role in the regulation of G1/S transitions and has been shown to interact with the cyclin D1 protein. This interaction between LINC01648 and cyclin D1 suggests that LINC01648 may be involved in the regulation of cell cycle progression and the timing of cell division.

Another function of LINC01648 is its role in regulating apoptosis. LINC01648 has been shown to play a role in the regulation of apoptosis by activating the BCL-2 gene. This interaction between LINC01648 and BCL-2 suggests that LINC01648 may be involved in the regulation of

Protein Name: Long Intergenic Non-protein Coding RNA 1648

The "LINC01648 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01648 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets